March 24, 2017 03:00 AM EDT
Pharma

No­var­tis lat­er­als two PhII an­ti-ag­ing drugs to a PureTech start­up, grab­bing an eq­ui­ty stake

John Carroll

Editor & Founder

Phar­ma gi­ant No­var­tis is spin­ning out a pair of Phase IIb-ready drugs now bound for ad­vanced tri­als on re­pair­ing the de­te­ri­o­rat­ing im­pact of ag­ing on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times